Results 211 to 220 of about 5,808 (257)

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager. [PDF]

J Mol Med (Berl)
Ebrahimi S, Lohnes BJ, Khan SA, Peipp M, Bockamp E, Klein C, Abken H, Wölfel C, Theobald M, Hartwig UF.   +9 more
europepmc   +1 more source

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. [PDF]

J Immunother Cancer
Gaspar M, Natoli M, Castan L, Rahmy S, Korade M, Kelton C, Mulgrew K, Huhn O, Rees DG, Sigurdardottir A, Lloyd C, Taylor JJ, Brailey PM, Dallaway L, Toloczko A, Giraldo N, Broggi MAS, Kunihiro A, Abhishek S, He Y, Rong Y, Eyles J, Ball K, Fitzgerald J, Hammond SA, Cemerski S, Dovedi SJ, Cobbold M.   +27 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

T-cell-engaging bispecific antibodies in cancer

The Lancet, 2023
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T cells to the tumour, followed by T-cell activation and degranulation, and tumour cell elimination.
Niels W C J, van de Donk, Sonja, Zweegman   +1 more
openaire   +2 more sources

T-cell–engaging Therapy for Solid Tumors

Clinical Cancer Research, 2020
Abstract T-cell engagers (TCE) are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T-cell surface molecule and a tumoral cell antigen. Bispecific antibodies and genetically engineered adoptive cell therapies, as chimeric antigen receptors or T-cell receptors, have similarities and ...
Maria de Miguel, Pablo Umana, Ana Luiza Gomes de Morais, Victor Moreno, Emiliano Calvo   +4 more
openaire   +2 more sources

T cell-engaging therapies — BiTEs and beyond

Nature Reviews Clinical Oncology, 2020
Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide an overview of the current status of bispecific T cell engager (BiTE) therapy, considering the unprecedented new indication for such therapy in combating minimal (or ...
Maria-Elisabeth Goebeler, Ralf C. Bargou
openaire   +2 more sources

Management of T-Cell Engaging Immunotherapy Complications

The Cancer Journal, 2019
Abstract The advent of T-cell–mediated immunotherapy has led to a new era in the treatment of relapsed, refractory B-cell lymphomas and leukemias. Chimeric antigen receptor T-cell and engineered T-cell receptor therapies have demonstrated impressive efficacy in treating refractory disease.
Indumathy, Varadarajan, Daniel W, Lee
openaire   +2 more sources

T-cell Engagers in Prostate Cancer

European Urology
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 ...
Chadi, Hage Chehade, Zeynep Irem, Ozay, Micah, Ostrowski, Chiara, Mercinelli, Georges, Gebrael, Nicolas, Sayegh, Umang, Swami, Arun A, Azad, Emmanuel S, Antonarakis, Neeraj, Agarwal   +9 more
openaire   +2 more sources

Bispecific T‐cell engagers for treatment of multiple myeloma

American Journal of Hematology, 2022
AbstractBispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for multiple myeloma (MM) target the B cell maturation antigen (BCMA) and differ among themselves ...
Gayathri Ravi, Luciano J. Costa
openaire   +2 more sources

T-cell engaging antibodies for B-cell lymphomas

Seminars in Hematology
T-cell engaging bispecific antibodies (BsAbs) have transformed the treatment paradigms for B-cell non-Hodgkin lymphomas. This review focused on 4 CD20 × CD3 BsAbs, as well as surovatamig, a CD19 × CD3 BsAb currently under investigation that has demonstrated promising efficacy against relapsed/refractory B-cell lymphomas.
Dong Hyun, Kim, Tae Min, Kim
openaire   +2 more sources

An Engaging Question of T Cell Receptors

Science's STKE, 2000
Signal desensitization occurs through several mechanisms involving the inhibition of receptors, intracellular signal mediators, or nuclear transcription factors. Cross-linking of the T cell receptor (TCR) leads to receptor activation followed by rapid desensitization. TCR internalization occurs through protein tyrosine kinase-dependent and
openaire   +2 more sources